ArticleVirologica Sinica2023

Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models.

Qiuxue Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.